SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001737287-22-000026
Filing Date
2022-04-26
Accepted
2022-04-26 16:28:23
Documents
7
Period of Report
2022-06-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A allo-20220414xdef14axdefin.htm DEF 14A 775966
2 drafproxyimage1.jpg GRAPHIC 19512
3 qualificationstable_31422.jpg GRAPHIC 187164
4 ceocompmix.jpg GRAPHIC 84484
5 otherneocompmix.jpg GRAPHIC 97322
6 proxycard1.jpg GRAPHIC 111981
7 proxycard2.jpg GRAPHIC 84123
  Complete submission text file 0001737287-22-000026.txt   1582403
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38693 | Film No.: 22854754
SIC: 2836 Biological Products, (No Diagnostic Substances)